Back

FIDELITY: Effect of finerenone by LVH subgroup

23 May 2022 (16:38 - 16:50)
Organised by:
Congress Presentation Part of: Late-Breaking Trials - Pharmacological treatment II Aldosterone Antagonists HFA Premium Access Heart Failure 2022

About the speaker

Photo
Professor Gerasimos Filippatos

National & Kapodistrian University of Athens Medical School, Athens (Greece)

4 More presentations in this session

Presentation thumbnail
The safety and efficacy of istaroxime for PreCardiogenic Shock
Professor M. Metra (Milan, IT)
Slides Video
Presentation thumbnail
Short-term effects of dapagliflozin on peak VO2 in heart failure and reduced ejection fraction (DAPA-VO2): a randomized clinical trial
Doctor J. Nunez Villota (Valencia, ES)
Slides Video
Presentation thumbnail
DIAMOND Trial: Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for Heart Failure with Reduced Ejection Fraction
Professor B. Pitt (Ann Arbor, US)
Slides Video
Presentation thumbnail
EMPULSE - EMPagliflozin in patients hospitalized with acUte heart faiLure who have been StabilizEd
Professor P. Ponikowski (Wroclaw, PL)
Slides Video

Access the full session

Session thumbnail
Late-Breaking Trials - Pharmacological treatment II
Video

The Event

Event poster

Heart Failure 2022

23 May 2022 16:38 CET
You may be interested in
thumbnail
Webinar
MRAs in heart failure: what's old is new again
thumbnail
Congress Presentation
Aldosterone-targeted therapies in hypertension
thumbnail
Congress Presentation
Aldosterone synthase inhibition

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources